AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 32717341
Drug: Infections requiring
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infections requiring a prescription
Trial: 32717341
Drug: Initiation in
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initiation in IOP medication
Trial: 33557924
Drug: Narrative enhancement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Narrative enhancement and cognitive therapy (NECT)
Trial: 32126028
Drug: Phacoemulsification without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phacoemulsification without ophthalmic viscosurgical devices (OVDs), using continuous irrigation mode and chopping technique.
Trial: 32455866
Drug: soy milk
RxNorm normalized name: DIMETHICONE 4 g in 100 g CUTANEOUS PATCH [FERMENTED SOY MILK WRINKLE CARE SLEEPING MASK]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: soy milk + PS (1.6 g/day)
Trial: 33113535
Drug: LI-guided therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LI-guided therapy
Trial: 32978540
Drug: General verbal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General verbal instructions on orthodontic treatment
Trial: 33838870
Drug: Insulin (20–40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin (20–40 mU/m2 per minute) and lipid (Intralipid) infusion
Trial: 34333391
Drug: Milk and
RxNorm normalized name: Suave Gentle Body Wash Milk and Honey
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk and rapeseed protein (35 g per day, ratio 54:46 or 30:70)
Trial: 34333391
Drug: Milk protein
RxNorm normalized name: Milk protein
DrugBank: Casein (DB10516)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milk protein alone (35 g per day)
Trial: 32067218
Drug: Metformin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin therapy for 6 months
Trial: 32067218
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (women with PCOS without metformin)
Trial: 35608580
Drug: Metformin 850
RxNorm normalized name: metFORMIN 850 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 850 mg orally twice a day (n = 1824)
Trial: 35608580
Drug: Placebo orally
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo orally twice a day (n = 1825)
Trial: 32130058
Drug: Sinetrol‐XPur (450
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sinetrol‐XPur (450 mg per tablet, 2 tablets once a day)
Trial: 32130058
Drug: Placebo (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2 tablets once a day)
Trial: 36014789
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg sodium butyrate twice a day (group A)
Trial: 32409838
Drug: Cefazolin added
RxNorm normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefazolin added to anesthetics (Group G)
Trial: 32409838
Drug: Conventional drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional drug group (Group C)
Trial: 34341520
Drug: Vosoritide (15.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vosoritide (15.0 μg/kg/day)
Trial: 34341520
Drug: Vosoritide (15.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vosoritide (15.0 μg/kg/day) after crossover from placebo
Trial: 33923532
Drug: Probiotic mixture
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic mixture containing Bifidobacterium animalis subsp. Lactis BB12 and Enterococcus faecium L3, administered daily for 3 months before allergen exposure
Trial: 32507490
Drug: Intranasal lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal lidocaine administration
Trial: 33989286
Drug: Music therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music therapy (twice a week from the 21st day of life till discharge)
Trial: 33291535
Drug: CHO_M (CHO–electrolyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHO_M (CHO–electrolyte solution + MBI)
Trial: 33291535
Drug: Control (non‐carbohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (non‐carbohydrate solution + travelling introduction audio)
Trial: 33291535
Drug: CHO (CHO–electrolyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CHO (CHO–electrolyte solution + travelling introduction audio)
Trial: 33823373
Drug: Compression force
RxNorm normalized name: Clean Force
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Compression force <82.5 N for CC
Trial: 33626250
Drug: BNT162b2 mRNA
RxNorm normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 Injectable Suspension [Comirnaty]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BNT162b2 mRNA vaccine (first dose, days 14-20)
Trial: 33626250
Drug: BNT162b2 mRNA
RxNorm normalized name: SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 Injectable Suspension [Comirnaty]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BNT162b2 mRNA vaccine (second dose, 7 or more days after)
Trial: 32819929
Drug: One dose
RxNorm normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One dose of tranexamic acid (TXA) 1g, intravenous injection 3 hours postsurgery
Trial: 32819929
Drug: Three doses
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three doses of tranexamic acid (TXA) 1g, intravenous injection at 3, 6, and 12 hours postsurgery
Trial: 32491923
Drug: Rectal 200
RxNorm normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rectal 200 mcg misoprostol
Trial: 32491923
Drug: Rectal 20
RxNorm normalized name: benzocaine
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rectal 20 mg hyoscine‐n‐butyl bromide
Trial: 33446284
Drug: Yohimbine (alpha2-adrenergic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yohimbine (alpha2-adrenergic antagonist)
Trial: 32056820
Drug: 30-minute music
RxNorm normalized name: TAGETES MINUTA FLOWER OIL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30-minute music therapy during colonoscopy
Trial: 35120199
Drug: Canagliflozin (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Canagliflozin (two doses)
Trial: 35262569
Drug: Hydroxychloroquine (HCQ)
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine (HCQ) 800 mg on day 1 and 400 mg from day 2 to day 7
Trial: 35381848
Drug: 20 mL
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mL rapeseed oil per day (RO)
Trial: 35381848
Drug: 20 mL
RxNorm normalized name: Exact-Med, 20 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mL sunflower oil per day (SO)
Trial: 32127178
Drug: Nonopioid-based analgesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonopioid-based analgesia (acetaminophen and ibuprofen)
Trial: 33098434
Drug: n-3 fatty
RxNorm normalized name: n-3 fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 fatty acids (1 g/day)
Trial: 34109697
Drug: 10‐mg ulipristal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10‐mg ulipristal acetate (UPA) once daily for three 12‐week courses
Trial: 32681739
Drug: Decitabine 10
RxNorm normalized name: cedazuridine-decitabine 100 mg-35 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decitabine 10 mg/m2 daily for 10 days plus dasatinib 100 mg daily
Trial: 32681739
Drug: Decitabine 20
RxNorm normalized name: Decitabine
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Decitabine 20 mg/m2 daily for 10 days plus dasatinib 100 mg daily
Trial: 32681739
Drug: Decitabine 10
RxNorm normalized name: cedazuridine-decitabine 100 mg-35 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decitabine 10 mg/m2 or 20 mg/m2 daily for 10 days plus dasatinib 140 mg daily (target dose)
Trial: 33503302
Drug: Triple-component single-pill
RxNorm normalized name: Triple Wormer Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple-component single-pill combination (olmesartan/amlodipine/hydrochlorothiazide 20/5/12.5 mg)
Trial: 33503302
Drug: Equivalent two-pill
RxNorm normalized name: Two-Dyne Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Equivalent two-pill regimen (olmesartan/hydrochlorothiazide 20/12.5 mg + amlodipine 5 mg)
Trial: 33272946
Drug: 2.8 mg
RxNorm normalized name: pectin 2.8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.8 mg folic acid
Trial: 33272946
Drug: 0 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 mg folic acid
Trial: 34962559
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D supplementation (120,000 IU of cholecalciferol monthly)
Trial: 32037556
Drug: Web-based survey
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Web-based survey assessing willingness to donate tissues for regenerative therapy
Trial: 32037556
Drug: Increased familiarity
RxNorm normalized name: Canis lupus familiaris skin
DrugBank: Canis lupus familiaris skin (DB10409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased familiarity with regenerative medicine through a brief paragraph of information
Trial: 34482306
Drug: Customized sound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Customized sound therapy with tinnitus sound matching (group A)
Trial: 34482306
Drug: Customized sound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Customized sound therapy without tinnitus sound matching (group B)
Trial: 32045406
Drug: Prolotherapy (PrT)
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolotherapy (PrT) injections
Trial: 32021173
Drug: NSB drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NSB drug capsules along with the standard of care treatment (Arm B)
Trial: 32021173
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care treatment (Arm A)
Trial: 34058888
Drug: 5% dextrose
RxNorm normalized name: LMD with 5% Dextrose
DrugBank: D-glucose (DB01914)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% dextrose solution
Trial: 36251378
Drug: Individualized behavioral
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individualized behavioral intervention to reduce daily sedentary behavior by 1 hour
Trial: 35789164
Drug: Topical calcipotriol
RxNorm normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical calcipotriol (0.005%) cream
Trial: 33973806
Drug: Ferulic acid
RxNorm normalized name: Ferulic acid
DrugBank: Ferulic acid (DB07767)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ferulic acid (200 mg)
Trial: 32295092
Drug: 4.5 g
RxNorm normalized name: Zosyn 4.5 GM Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.5 g of fructooligosaccharides + 2 g of maltodextrin (FOS group)
Trial: 32295092
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g of maltodextrin (placebo group)
Trial: 35833597
Drug: Liraglutide (1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide (1.2 mg)
Trial: 33217070
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (TAU; n = 30)
Trial: 32386744
Drug: Antimalarial drugs
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antimalarial drugs
Trial: 32469305
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation of acetylsalicylic acid (81 mg)
Trial: 32469305
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation of acetylsalicylic acid (Ecasil-81, 81 mg)
Trial: 32469305
Drug: Food intake
RxNorm normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Food intake during administration
Trial: 616063739
Drug: Intermediate or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermediate or full doses of epirubicin-cyclophosphamide
Trial: 34710105
Drug: Local-ingredients-based supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local-ingredients-based supplement (LIBS)
Trial: 32366320
Drug: Mindfulness-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-based cognitive therapy self-help (MBCT-SH)
Trial: 32366320
Drug: Cognitive behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioural therapy self-help (CBT-SH)
Trial: 35325665
Drug: Burst physical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Burst physical therapy (two PT sessions weekly for 6 weeks)
Trial: 35325665
Drug: Spaced physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spaced physical therapy (one PT session every 2 weeks for 6 months)
Trial: 34377150
Drug: Naldemedine 0.2
RxNorm normalized name: naldemedine 0.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naldemedine 0.2 mg
Trial: 35561315
Drug: Iptacopan 25
RxNorm normalized name: Iptacopan
DrugBank: Iptacopan (DB16200)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iptacopan 25 mg for 4 weeks followed by 100 mg for up to 2 years (cohort 1)
Trial: 35561315
Drug: Iptacopan 50
RxNorm normalized name: Iptacopan
DrugBank: Iptacopan (DB16200)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iptacopan 50 mg for 4 weeks followed by 200 mg for up to 2 years (cohort 2)
Trial: 33177265
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups received treatment for BPSD.
Trial: 32764111
Drug: Oral corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral corticosteroids (OCS)
Trial: 38299639
Drug: Antimalarial therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antimalarial therapy
Trial: 33888139
Drug: Ceftolozane-tazobactam 3
RxNorm normalized name: ceftolozane / tazobactam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftolozane-tazobactam 3 g every 8 hours
Trial: 35403225
Drug: Senicapoc (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Senicapoc (50 mg enteral) administered as soon as possible after randomization and again after 24 hours.
Trial: 35403225
Drug: Senicapoc (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Senicapoc (50 mg enteral).
Trial: 36285404
Drug: Targeted oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Targeted oral naltrexone (50 mg) with weekly counseling for 12 weeks
Trial: 34045905
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg WDTE60N capsule (150 mg curcuminoids)
Trial: 35212740
Drug: High-protein and
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-protein and fiber-based multi-ingredient nutritional shake (HPF) (17 g protein, 6 g fiber)
Trial: 35212740
Drug: Low-protein, lower
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-protein, lower fiber-based placebo (LPF) (1 g protein, 3 g fiber)
Trial: 35318120
Drug: GnRH antagonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH antagonist protocol with high LH levels on day six
Trial: 35318120
Drug: GnRH antagonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH antagonist protocol with low LH levels on day six
Trial: 35318120
Drug: GnRH antagonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH antagonist protocol with medium LH levels on day six
Trial: 36273991
Drug: Per-oral pancreatoscopy-guided
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Per-oral pancreatoscopy-guided lithotripsy (POP)
Trial: 35405168
Drug: BNT (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BNT (15 μg)
Trial: 32772737
Drug: Oral medications
RxNorm normalized name: Medicated Shampoo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral medications (including voltage‐gated calcium channels antagonists, voltage‐gated sodium channel antagonists, serotonin‐norepinephrine reuptake inhibitors, NMDA antagonists)
Trial: 37349498
Drug: Ibuprofen 400
RxNorm normalized name: ibuprofen 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen 400 mg/Paracetamol 1000 mg
Trial: 37349498
Drug: Ibuprofen 400
RxNorm normalized name: ibuprofen 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen 400 mg/Paracetamol 1000 mg/Codeine 60 mg
Trial: 37349498
Drug: Paracetamol 1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol 1000 mg/Codeine 60 mg
Trial: 34097231
Drug: 10 days
RxNorm normalized name: AlleRx 10-day Dose Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 days of antibiotic therapy
Trial: 36501014
Drug: l-arginine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l-arginine plus vitamin C
Trial: 32740409
Drug: Aliskiren (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aliskiren (150 mg once daily, n=9)
Trial: 32740409
Drug: Ramipril (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramipril (5 mg once daily, n=7)
Trial: 32740409
Drug: Aliskiren (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aliskiren (150 mg once daily)
Trial: 36265052
Drug: 0.60 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.60 g/kg alcohol
Trial: 32238262
Drug: Antibiotic-impregnated shunt
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antibiotic-impregnated shunt
Trial: 32552530
Drug: Laughter yoga
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Laughter yoga (LY) twice weekly for 8 weeks
Trial: 32552530
Drug: Routine daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine daily activities (Control)
Trial: 33165588
Drug: Availability of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Availability of medicines and supplies for communicable diseases
Trial: 33165588
Drug: Availability of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Availability of medicines and supplies for maternal health services
Trial: 34344427
Drug: Green tea
RxNorm normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Green tea extract (450 mg, two capsules twice a day for 14 days)
Trial: 34344427
Drug: Placebo (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (two capsules twice a day for 14 days)
Trial: 39541403
Drug: Cisplatin treatment
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin treatment
Trial: 34213544
Drug: High-dose prenatal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose prenatal plus postpartum vitamin D (28,000 IU per week)
Trial: 34246303
Drug: LOW (1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LOW (1.5 g/kg carbohydrate, 3.0 g/kg fat)
Trial: 34246303
Drug: AD (6.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AD (6.0 g/kg carbohydrate, 1.0 g/kg fat)
Trial: 34945234
Drug: Remote hospital
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remote hospital care including oxygen therapy, medication, and remote monitoring.
Trial: 35662283
Drug: Nivolumab (nivo)
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nivolumab (nivo) with chemotherapy (gemcitabine/nab-paclitaxel)
Trial: 35662283
Drug: Sotigalimab (sotiga)
RxNorm normalized name: Sotigalimab
DrugBank: Sotigalimab (DB16413)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sotigalimab (sotiga) with chemotherapy (gemcitabine/nab-paclitaxel)
Trial: 35662283
Drug: Sotigalimab (sotiga)
RxNorm normalized name: Sotigalimab
DrugBank: Sotigalimab (DB16413)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sotigalimab (sotiga) with nivolumab (nivo) and chemotherapy (gemcitabine/nab-paclitaxel)
Trial: 36691184
Drug: Post-chemotherapy
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-chemotherapy
Trial: 36342113
Drug: Pemafibrate (0.2-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemafibrate (0.2-mg tablets twice daily)
Trial: 36978099
Drug: Intermittent therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent therapy
Trial: 34501540
Drug: Multifaceted intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multifaceted intervention program (interactive oral activities, tongue strength training, oral cleaning procedure)
Trial: 33615398
Drug: CBT combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBT combined with medication (CBT + M)
Trial: 33615398
Drug: Medication only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication only (M)
Trial: 34347808
Drug: Oral phloroglucinol
RxNorm normalized name: phloroglucinol
DrugBank: Phloroglucinol (DB12944)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral phloroglucinol (Flospan®)